Pharma & Bio
Technology
"Full-Scale Commercialization to Begin Next Year"... Space Rintec's Blueprint for Space CRO and CDMO Services
"Developing new drugs in space reduces costs to one-tenth of the original amount. This will create a foundation for domestic pharmaceutical companies to develop new drugs quickly and at a lower cost."…
IPO
Choi Seong-gu, CEO of FINO INC.: "Final Stages of ADC Platform Validation… Pursuing Asset Deals with Our Own Pipeline"
“I believe this will be our final attempt at an IPO. We are approaching this very cautiously, with the mindset that there will be no more chances.” (Choi Seong-gu, President of FINO INC.)PinoBio, a de…
Lifestyle
Mixed Market, Solid Footing: Psomagen and Jetema Stand Out [K-Bio Pulse]
While the domestic stock market has recently remained mixed and struggled to find a clear direction, the pharmaceutical and biotech sectors have carved out an upward trajectory. This rally is backed b…
Lifestyle
Amid a Mixed Stock Market, Psomagen, Inc. and JETEMA Co.,Ltd. Stand Out [Bio Spotlight]
While the domestic stock market has recently been showing mixed trends without a clear direction, the pharmaceutical and biotech sectors have been on an upward trend, driven by clear prospects for ear…
Lifestyle
Noh Hae-sung, CTO of GENINUS Inc.: “Patient Data Determines Success or Failure in AI-Driven New Drug Development… Spatial Omics Is the Answer”
“Going forward, success or failure in AI-driven new drug development will hinge not on having better AI models, but on who secures better data.”Noh Hae-sung GENINUS Inc.(389030), Head of Research and …
Technology
Lee Soo-jin, CEO of Aptabio Therapeutics Inc.: “We’re Targeting the Post-Lenvima Era… APX-343A as a Combination Therapy with Keytruda”
“We are not trying to compete with existing immunotherapy drugs. APX-343A’s role is to make existing immunotherapy drugs more effective.”As competition in the development of immuno-oncology drugs ente…
Technology
InBody Rallies on GLP-1 Buzz, Cellid Sinks [K-Bio Pulse]
Shares of South Korean biotech companies moved sharply in different directions on Monday as company-specific developments drove investor sentiment. InBody extended its rally and climbed to a fresh 52-…
Technology
GLP-1 Tailwinds: InBody Co., Ltd. and Synergy Expected for ARIBIOLAB… Cellid Co., Ltd. Faces ‘Clinical Setback’ [Bio Spotlight]
On the 30th, while stock prices of domestic pharmaceutical, biotech, and healthcare companies were generally sluggish, a few companies stood out with strong performance. InBody Co., Ltd.(041830)contin…
Lifestyle
Ensol Bio Makes Another Attempt at Relisting on KOSDAQ... ‘Green Light’ as It Demonstrates Profitability and Technological Capabilities
Ensol Biosciences (hereinafter “Ensol Bio”), a company specializing in the development of innovative new drugs, is moving full steam ahead with its transfer listing to KOSDAQ. Unlike its previous atte…
Lifestyle
New Approach to Treating Fishy Odor Syndrome… Yoon Sang-seon, CEO of Biomi: “Directly Breaking Down TMA in the Gut”
“Telling patients with fishy odor syndrome not to eat eggs or meat is not a realistic treatment. People have to eat to survive.”These were the first words heard during an exclusive interview conducted…